NASDAQ:GYRE Gyre Therapeutics Q2 2026 Earnings Results & Report $4.74 +0.44 (+10.09%) As of 01:06 PM Eastern This is a fair market value price provided by Massive. Learn more. Gyre Therapeutics missed analyst earnings expectations but beat on revenue in its Q2 2026 results, released August 7, 2026. The company reported EPS of -$0.12 versus the -$0.0567 consensus estimate, while revenue of $29.11 million topped the $26.49 million estimate by $2.62 million. Research:ProfileEarnings HistoryForecast Earnings Announcement Details QuarterQ2 2026Report DateAugust 7, 2026TimeBefore Market OpensConference Call9:30 AM ET Gyre Therapeutics EPS ResultsActual EPS-$0.12Consensus EPS -$0.0567Beat/MissMissed by -$0.0633One Year Ago EPSN/AEPS Beat Rate2 of last 8 quartersGyre Therapeutics Revenue ResultsActual Revenue$29.11 millionExpected Revenue$26.49 millionBeat/MissBeat by +$2.62 millionYoY Revenue GrowthN/AConference Call ResourcesPress Release (8-K)Quarterly Report (10-Q)SEC FilingEarnings HistoryCompany ProfilePowered by Earnings DocumentsPress Release(8-K)Quarterly report(10-Q) Gyre Therapeutics Q2 2026 Earnings FAQ Did Gyre Therapeutics beat earnings estimates for Q2 2026? Gyre Therapeutics (NASDAQ:GYRE) reported earnings of -$0.12 per share for Q2 2026, missing the consensus estimate of -$0.0567. The report was announced on Friday, August 7, 2026. What was Gyre Therapeutics' revenue for Q2 2026? Gyre Therapeutics reported revenue of $29.11 million for Q2 2026, against a consensus estimate of $26.49 million. Gyre Therapeutics Earnings HeadlinesGyre Therapeutics (NASDAQ:GYRE) Shares Climb 14.5% After Strong EarningsNovember 8, 2026 | americanbankingnews.comGyre Therapeutics (NASDAQ:GYRE) Stock Rating Raised to "Hold" at Wall Street ZenNovember 7, 2026 | americanbankingnews.comMy $247 scanner for $7Bill Poulos is cutting the price of his $247 Instant Scanner to $7 for Black Friday. It's a one-time payment that covers a full year, with no subscription and no re-bills. Every night after the close, the scanner screens nearly a thousand of America's biggest stocks. It returns a short list of qualifying setups with the exact buy price next to each one. There's nothing to install. If you decide it's not for you, you get the $7 back and keep the scanner for the year.November 16 at 1:00 AM | Profits Run (Ad)Gyre Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2026November 5, 2026 | marketscreener.comMGyre Therapeutics Reports Third Quarter 2026 and Year-to-Date Financial Results with Business UpdatesNovember 5, 2026 | globenewswire.comGyre Therapeutics, Inc. enters into new employment agreements on October 16, 2026October 22, 2026 | msn.comSee More Gyre Therapeutics Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Gyre Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Gyre Therapeutics and other key companies, straight to your email. Email Address About Gyre TherapeuticsGyre Therapeutics (NASDAQ:GYRE) is a biopharmaceutical company focused on developing and commercializing treatments for liver and other chronic diseases. The company operates in the United States and China, including through its China-based subsidiary, Beijing Continent Pharmaceuticals. Its pipeline includes hydronidone, also known as F351, an oral drug candidate being developed for liver fibrosis associated with chronic hepatitis B. Gyre is also developing treatments for other serious conditions, including acute-on-chronic liver failure. The company adopted the Gyre Therapeutics name in 2023, following its predecessor Catalyst Biosciences’ acquisition of a majority stake in Gyre Pharmaceuticals. This brought together U.S.-based drug development activities and established pharmaceutical operations in China.View Gyre Therapeutics ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles 3 Building-Materials Stocks Rallying While Homebuilders Struggle to Find BuyersMarketBeat Week in Review – 11/9 - 11/133 AI Hardware Leaders Are Raising Dividends, But Which Offers More Income?Nu Holdings Earnings Show a Compounder Priced Like a Brazil BetCould Big Buybacks Be the Next Catalyst for These 3 AI Stocks?Cerebras Q3 Results: How Much More Proof Does Wall Street Need?Nebius Revenue Is Surging, But Its Spending Is Raising Bigger Questions Upcoming Earnings Walt Disney (11/17/2026)Home Depot (11/17/2026)NVIDIA (11/17/2026)Lowe's Companies (11/18/2026)TJX Companies (11/18/2026)Target (11/18/2026)Palo Alto Networks (11/18/2026)NetEase (11/19/2026)Alibaba Group (11/19/2026)PDD (11/19/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.